肺癌微转移检测与分子分期的研究进展  

Research progress on micrometastases detection and molecular staging of lung cancer

作　　者：曾薇[1] 李惠武[2] 

机构地区：[1]新疆医科大学附属肿瘤医院肺内科一病区,乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院肿瘤研究所,830011

出　　处：《临床肿瘤学杂志》2013年第9期850-856,共7页Chinese Clinical Oncology

摘　　要：目前,国际通用的肺癌TNM分期法对肺癌治疗策略的制定和预后的判断有重要意义,但相同TNM分期的预后存在差异可能由于肿瘤微转移所致。利用分子生物学的技术手段和标记物检测肿瘤微转移以及在TNM分期的基础上进行肺癌分子分期,可以弥补TNM分期的不足,使诊断精确到分子水平。依据肺癌分子分期,制定规范化的治疗方案,对于降低肿瘤复发、转移及改善预后有重要意义。The current international TNM staging for lung cancer plays an important role in the development of treatment strat- egies and prognosis judgment of lung cancer. The prognosis differs among patients in the same stages, probably due to tumor microme- tastases. The tumor micrometastases can be detected by molecular biology techniques and molecular markers. On the basis of TNM classification, the molecular staging of lung cancer can be developed to remedy the deficiency of TNM staging system. With the molecu- lar staging of lung cancer, the development of standardized treatment program is of importance to reduce tumor recurrence and metasta- ses, as well as improve prognosis.

关 键 词：非小细胞肺癌 微转移 分子分期 

分 类 号：R734.2[医药卫生—肿瘤]